前列腺导管腺癌诊疗进展

The progress of the clinical implication and management of prostate ductal adenocarcinoma

导管腺癌(ductal adenocarcinoma,DAC)是前列腺癌最常见的组织学亚型变异,具有侵袭性的临床病程。由于疾病罕见,传统的诊断方式如血清前列腺特异性抗原(prostate-specific antigen,PSA)和多参数MRI可能难以识别DAC,局部DAC的最佳治疗模式尚在探索。局限性DAC进行根治性前列腺切除术或放疗后,大多数DAC易在低PSA水平下复发或发生内脏转移,针对高危前列腺癌的全身疗法在DAC的治疗中疗效欠佳。目前,DAC基因组学的分析已为其侵袭性行为和潜在治疗靶点提供了实验室证据,但对DAC生物学行为机制的探索仍需继续推进。

Ductal adenocarcinoma(DAC)is the most common histological variant of prostate cancer with an aggressive characteristic.Due to the rarity of the disease,DAC can be difficult to identify by traditional diagnostic modalities such as serum prostate-specific antigen(PSA)and multi-parameter magnetic resonance imaging.Optimal treatment mode for local DAC is still under exploration.After radical prostatectomy or radiotherapy,most DACs are prone to recurrence or metastasis at low PSA levels,and systemic therapy for high-risk prostate cancer is less effective in the treatment of DAC.Current genomic analysis of DAC has provided laboratory evidence for its aggressive behavior and potential therapeutic targets,but the exploration of the mechanism of the biological behavior of DAC still needs to be addressed.